Abstracts Archive - Page 2258 of 2425 - ACR Meeting Abstracts

Abstract Number: 2480 • 2012 ACR/ARHP Annual Meeting
Disease-Modifying Antirheumatic Drug Use and Toxicities Among Elderly Patients with Rheumatoid Arthritis
Rebecca L. Manno¹, Dimitrios A. Pappas², Katherine C. Saunders³, George Reed⁴, Shannon Grant⁵ and Clifton O. Bingham III⁶, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²New York Presbyterian Hospital, Columbia University, College of Physicians & Surge, New York, NY, ³Corrona, LLC., Southborough, MA, ⁴Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, ⁵Axio Research LLC, Seattle, WA, ⁶Department of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: The aging population has resulted in large numbers of older individuals requiring treatment for rheumatoid arthritis (RA). We sought to describe the clinical characteristics…
Abstract Number: 2481 • 2012 ACR/ARHP Annual Meeting
Time Trends in Corticosteroid Use in Rheumatoid Arthritis: Results From a Population Based Inception Cohort 1980–1994 Vs. 1995–2007
Ashima Makol¹, John M. Davis III², Cynthia S. Crowson³, Terry M. Therneau³, Sherine E. Gabriel⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Corticosteroids (CS) are a double edged sword in rheumatoid arthritis (RA) treatment. Low doses may have disease modifying effects but long-term use risks detrimental…
Abstract Number: 2482 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Has Lipid-Lowering Effects in US Veterans with Rheumatoid Arthritis
Nicole A. Kieffer¹, Gail S. Kerr², J. Steuart Richards³, Lisa A. Davis⁴, Liron Caplan⁵, Jeffrey Huang⁶, Grant W. Cannon⁷, Harlan Sayles⁸ and Kaleb Michaud⁹, ¹Division of Rheumatology, Georgetown University, Washington, DC, ²Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ³Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ⁴Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁵Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ⁶Rheumatology, Washington DC VA and Howard University Hospital, Washington, DC, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent data report significant decreases in low-density lipoprotein (LDL) and total cholesterol (TC) levels in predominantly female Caucasian rheumatoid arthritis (RA) patients treated with…
Abstract Number: 2483 • 2012 ACR/ARHP Annual Meeting
Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events
Lisa A. Davis¹, Brooke Ivan Polk², Alyse D. Mann³, Roger K. Wolff⁴, Gail S. Kerr⁵, Andreas M. Reimold⁶, Grant W. Cannon⁷, Ted R. Mikuls⁸ and Liron Caplan⁹, ¹Div of Rheumatology, Univ of Colorado School of Med, Aurora, CO, ²University of Colorado Medical School, Aurora, CO, ³Research, Denver VA Medical Center, Denver, CO, ⁴University of Utah, Salt Lake City, UT, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Methotrexate (MTX) is the cornerstone medication in the treatment of rheumatoid arthritis (RA). While MTX has been associated with a number of adverse…
Abstract Number: 2484 • 2012 ACR/ARHP Annual Meeting
Hepatic Steatosis in Rheumatoid Arthritis: Associations with Disease Characteristics, Pharmacotherapies, and Atherosclerosis
Jon T. Giles¹ and Joan M. Bathon², ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Columbia University, New York, NY
Background/Purpose: Ectopic deposition of liver fat (steatosis) is associated with insulin resistance (IR), cardiovascular disease (CVD), and is a potent risk factor for cirrhosis. RA…
Abstract Number: 2485 • 2012 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population
S. Cohen¹, S. Krishnaswami², B. Benda³, R. Riese², M.G. Boy⁴, D. Gruben⁴, G. Wallenstein⁵, C. A. Mebus⁴, S. H. Zwillich² and J. D. Bradley⁶, ¹Metroplex Clinical Research Centre, Dallas, TX, ²Pfizer Inc., Groton, CT, ³Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…
Abstract Number: 2446 • 2012 ACR/ARHP Annual Meeting
Activity Limitations Experienced by People with Rheumatoid Arthritis On Biologic Medications and Their Use of Ergonomic Methods
Alison Hammond¹ and Sarah Tyson², ¹Centre for Health Sciences Research, University of Salford, Salford, United Kingdom, ²Centre for Health Sciences Research, University of Salford, Manchester, United Kingdom
Background/Purpose: People with rheumatoid arthritis (RA) commonly have daily activity difficulties. Whilst biologics significantly improve ability, ergonomic methods (e.g. altered working methods, ergonomic equipment, activity…
Abstract Number: 2447 • 2012 ACR/ARHP Annual Meeting
Accuracy of Sensewear Mini^TM and Actigraph GT3X^TM Accelerometers for Differentiating Sedentary and Light Physical Activities in a Controlled Laboratory Setting
April Y. F. Leung¹, Lynne M. Feehan², Cynthia Macdonald¹, Jenny Leese³, Erin Carruthers⁴ and Linda C. Li⁵, ¹Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ²Physical Therapy, Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: People living with inflammatory arthritis are likely to be less physically active due to pain and fatigue. To understand the relationship between physical inactivity…
Abstract Number: 2448 • 2012 ACR/ARHP Annual Meeting
Sustained Improvement Physical Function Following an Integrated Rehabilitation Programme for Chronic Knee Pain
Mike Hurley¹ and Dr Nicola E. Walsh², ¹School of Rehabilitation Sciences, St George's University of London, London, United Kingdom, ²Allied Health Professions, University of the West of England Bristol, Bristol, United Kingdom
Background/Purpose: Chronic knee pain causes personal suffering and impairs physical function and quality of life. Usual primary care involves prolonged drug therapy in spite of…
Abstract Number: 2449 • 2012 ACR/ARHP Annual Meeting
Head to Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Michael E. Weinblatt¹, Michael H. Schiff², Roy Fleischmann³, Robert Valente⁴, Désirée van der Heijde⁵, Gustavo Citera⁶, Cathy Zhao⁷ and Michael A. Maldonado⁸, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology Division, University of Colorado, Denver, CO, ³Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁴Arthritis Center of Nebraska, Lincoln, NE, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose : The availability of multiple biologic agents to treat rheumatoid arthritis (RA) has created a need for comparative assessment. AMPLE (Abatacept Versus Adalimumab Comparison…
Abstract Number: 2450 • 2012 ACR/ARHP Annual Meeting
Evoked Pain Brain Response Is Associated with Reduced μ-Opioid Receptor Binding in Fibromyalgia
Heng Wang¹, Daniel J. Clauw², Jon-Kar Zubieta³ and Richard E. Harris⁴, ¹Anesthesiology, University of Michigan, Ann Arbor, ²Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ³Molecular and Behavioral Neuroscience Institue, Psychiatry, University of Michigan, Ann Arbor, ⁴Anesthesiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Previous studies indicate that fibromyalgia (FM) patients have augmented clinical and brain responses to painful stimuli (i.e. hyperalgesia/allodynia), as well as increased production of…
Abstract Number: 2451 • 2012 ACR/ARHP Annual Meeting
Laquinimod (LAQ) Is Equivalent to Mycophenolate Mofetil (MMF) in Preventing and Suppressing Murine Lupus Nephritis and Has Greater Effects On Myeloid/Monocyte/Macrophage Cells
Bevra H. Hahn¹, Maida Wong², Elaine Lourenco² and Brian Skaggs², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Lupus nephritis (LN) depends on autoAb deposition and activation of multiple cell types that infiltrate kidneys and promote inflammation – monocytes/macrophages (MM), DCs, T…
Abstract Number: 2452 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated PTPN22 Modulates Toll-Like Receptor-Mediated, Type 1 Interferon-Dependent Innate Immunoregulation
Yaya Wang¹, Stephanie Stanford², Wenbo Zhou³, Jennifer L. Auger⁴, Genhong Cheng⁵, Amanda Campbell⁶, Fernanda M. Shoyama¹, Henry H. Balfour Jr.⁷, Andrew C. Chan⁸, Bryce A. Binstadt⁴, Nunzio Bottini⁶ and Erik J. Peterson³, ¹Department of Medicine, University of Minnesota, Minneapolis, MN, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³University of Minnesota, Minneapolis, MN, ⁴Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ⁵University of California, Los Angeles, Los Angeles, CA, ⁶La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁷University of Minnesota, Minneapolis, ⁸Immunology, Genentech Inc, South San Francisco, CA
Background/Purpose: A coding polymorphism (C1858T) in PTPN22 is strongly associated with risk of Rheumatoid Arthritis (RA) and other autoimmune diseases. PTPN22 encodes Lymphoid Phosphatase (Lyp);…
Abstract Number: 2453 • 2012 ACR/ARHP Annual Meeting
The Role of Bob1 in Rheumatoid Arthritis: Potential Implications for Autoimmunity
Nataliya Yeremenko¹, Tineke Cantaert¹, Melissa N. van Tok², Ioana Gofita¹, Juan D. Canete³, Paul P. Tak⁴, Hergen Spits⁵ and Dominique L. Baeten⁴, ¹Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ³Arthritis Unit. Rheumatology Department, Hospital Clínic, Barcelona, Spain, ⁴Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Tytgat Institute for Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies such…
Abstract Number: 2454 • 2012 ACR/ARHP Annual Meeting
Expression of TLR5 Strongly Correlates with Levels of TNF-a and DAS28 in RA Monocytes and Ligation of TLR5 Induces Angiogenesis in RA
Nathan D. Chamberlain¹, Michael Volin², Olga M. Vila³, Shiva Arami⁴, Suncica Volkov⁵ and Shiva Shahrara¹, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²Department of Microbiology and Immunology, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, ³University of Illinois at Chicago, Chicago, IL, ⁴Medicine - Rheumatology, University of Illinois at Chicago, Chicago, IL, ⁵Rheumatology/MC 733, University of Illinois at Chicago, Chicago, IL
Background/Purpose: This study was performed to determine whether expression of TLR5 is associated with Rheumatoid Arthritis (RA) disease activity as well as to examine the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].